

Citation: Fugmann M, Uhl O, Hellmuth C, Hetterich H, Kammer NN, Ferrari U, et al. (2015) Differences in the Serum Nonesterified Fatty Acid Profile of Young Women Associated with a Recent History of Gestational Diabetes and Overweight/Obesity. PLoS ONE 10(5): e0128001. doi:10.1371/journal. pone.0128001

Academic Editor: Juergen Eckel, GDC, GERMANY

Received: December 12, 2014

Accepted: April 21, 2015

Published: May 26, 2015

Copyright: © 2015 Fugmann et al. This is an open access article distributed under the terms of the <u>Creative Commons Attribution License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by Helmholtz Zentrum München: <u>http://www.helmholtz-muenchen.</u> <u>de/en/</u> (AL, JS), Klinikum der Universität München: <u>http://www.klinikum.uni-muenchen.de/de/index.html</u> (AL, JS), and German Center for Diabetes Research: <u>http://www.dzd-ev.de/index.html</u> (AL, JS).

Competing Interests: The authors have declared that no competing interests exist.

RESEARCH ARTICLE

Differences in the Serum Nonesterified Fatty Acid Profile of Young Women Associated with a Recent History of Gestational Diabetes and Overweight/Obesity

Marina Fugmann^{1,2,3}, Olaf Uhl⁴, Christian Hellmuth⁴, Holger Hetterich⁵, Nora N. Kammer⁵, Uta Ferrari^{1,2,3}, Klaus G. Parhofer⁶, Berthold Koletzko⁴, Jochen Seissler^{1,2,3}, Andreas Lechner^{1,2,3}*

 Diabetes Research Group, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany, 2 Clinical Cooperation Group Type 2 Diabetes, Helmholtz Zentrum München, Munich, Germany, 3 German Center for Diabetes Research (DZD), Munich, Germany, 4 Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's Hospital, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany, 5 Institute for Clinical Radiology, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany,
Medizinische Klinik und Poliklinik II, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany

* andreas.lechner@med.uni-muenchen.de

Abstract

Background

Nonesterified fatty acids (NEFA) play pathophysiological roles in metabolic syndrome and type 2 diabetes (T2D). In this study, we analyzed the fasting NEFA profiles of normoglycemic individuals at risk for T2D (women with a recent history of gestational diabetes (GDM)) in comparison to controls (women after a normoglycemic pregnancy). We also examined the associations of NEFA species with overweight/obesity, body fat distribution and insulin sensitivity.

Subjects and Methods

Using LC-MS/MS, we analyzed 41 NEFA species in the fasting sera of 111 women (62 post-GDM, 49 controls). Clinical characterization included a five-point oral glucose tolerance test (OGTT), biomarkers and anthropometrics, magnetic resonance imaging (n = 62) and a food frequency questionnaire. Nonparametric tests with Bonferroni correction, binary logistic regression analyses and rank correlations were used for statistical analysis.

Results

Women after GDM had a lower molar percentage of total saturated fatty acids (SFA; 38.55% vs. 40.32%, p = 0.0002) than controls. At an explorative level of significance several NEFA species were associated with post-GDM status (with and without adjustment for body mass index (BMI) and HbA1c): The molar percentages of 14:0, 16:0, 18:0 and 18:4 were

reduced, whereas those of 18:1, 18:2, 20:2, 24:4, monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA) and total n-6 NEFA were increased. BMI and the amount of body fat correlated inversely with several SFA and MUFA and positively with various PUFA species over the whole study cohort ($abs(\rho) \ge 0.3$ for all). 14:0 was inversely and BMI-independently associated with abdominal visceral adiposity. We saw no correlations of NEFA species with insulin sensitivity and the total NEFA concentration was similar in the post-GDM and the control group.

Conclusion

In conclusion, we found alterations in the fasting NEFA profile associated with a recent history of gestational diabetes, a risk marker for T2D. NEFA composition also varied with overweight/obesity and with body fat distribution, but not with insulin sensitivity.

Introduction

Several lines of evidence suggest that NEFA are involved in the pathogenesis of T2D via a reduction of insulin sensitivity and the promotion of pancreatic beta cell apoptosis and dysfunction [1-3]. Particularly in the context of metabolic syndrome, NEFA might represent an important link between obesity and insulin resistance [4, 5]. However, it is not entirely clear whether elevated serum NEFA levels in individuals with T2D or metabolic syndrome are a primary disease-inducing alteration or a secondary change [6, 7].

Different NEFA species have distinct effects on insulin sensitivity, beta cell function and tissue inflammation in experimental setups [8]. SFA, for instance, are able to interact with toll-like receptor 4 (TLR-4) to induce proinflammatory signaling [9], whereas PUFA, such as docosahexaenoic acid (22–6 n-3), inhibit these pathways, e.g., by binding to G protein-coupled receptor 120 [10].

Previous studies have shown differences in the serum NEFA composition between individuals with T2D or metabolic syndrome and controls [11, 12]. We wanted to test the hypothesis that the serum NEFA profile is also altered in a specific cohort of young, normoglycemic individuals with a high risk for T2D, namely in women after GDM. We chose a recent history of GDM to select the at-risk cohort because no reliable biomarkers are available to identify T2D at-risk subjects while they are still normoglycemic. Women with GDM during a recent pregnancy however have an about 10-fold increased risk for subsequent T2D within 10 years and therefore represent a suitable population to address our research question [13, 14]. Women after a normoglycemic pregnancy were included in the study as controls. We also examined the associations of the fasting NEFA profile with body fat distribution and insulin resistance.

Subjects and Methods

Study population

Between November 2011 and December 2013 147 women were consecutively recruited within the prospective Prediction, Prevention and Subclassification of Type 2 Diabetes (PPS-Diab) cohort study [15]. Gestational diabetes and normoglycemia during pregnancy were diagnosed with a 75g OGTT between the 24th and the 28th week of gestation following the IADPSG criteria [16]. For this analysis, 111 women (62 cases after GDM and 49 controls) were included due to normoglycemia at the baseline visit between 3 and 16 months after delivery. Over 90% of the

study participants were Caucasian. Exclusion criteria for this study were chronic diseases requiring medication except for hypothyroidism. Hormonal contraception was also permitted. Written informed consent was obtained from each subject and the study was approved by the ethics committee of the Ludwig-Maximilians-Universität München.

Anthropometric and clinical measurements

Weight and fat mass were measured using a bioelectrical impedance analysis (BIA) scale (Tanita BC-418, Tanita Corporation, Tokyo, Japan). BMI was calculated as the weight (in kilograms) divided by height squared (in meters). Hip and waist circumferences (WC) were assessed by tape measurements. Daily physical activity (m/d) was measured by a pedometer (AiperMotion 440, Aipermon GmbH & Co. KG, Munich, Germany). A 5-point 75 g OGTT was performed once. Normoglycemia was defined as fasting blood glucose <100mg/dl and 2 hour blood glucose <140mg/dl. During the OGTT, blood pressure readings were obtained three times from all subjects in a sitting position. A food frequency questionnaire (EPIC-FFQ) for the assessment of dietary nutritional intake was completed online by the majority of the study participants (n = 87) [17]. In a subgroup of women (n = 62, consisting of 37 cases and 25 controls) whole body fat and abdominal subcutaneous and visceral fat were measured with an axial T1w or mDixon magnetic resonance imaging (MRI) technique [18] on a 3.0 Tesla scanner (Philips Healthcare, Best, The Netherlands). Liver fat was assessed with fat fraction maps generated from mDixon sequences [19].

Blood sample collection and analysis

Analysis of serum NEFA. After 30 minutes of coagulation time, serum monovettes were centrifuged at 2000 g at room temperature. Serum aliquots were then immediately frozen on dry ice and stored at -80°C until analysis. The total NEFA concentrations were determined by an enzymatic calorimetric method (NEFA Kit, Wako Chemicals, Neuss, Germany). For quantification of the NEFA species, 20 μ l of each serum sample was mixed with 200 μ l isopropanol (containing the internal standard) in a 96-deepwell plate. After centrifugation, the supernatant was used for NEFA analysis by LC-MS/MS as previously described [20]. The NEFA were identified according to chain length and the number of double bonds. The positions of double bonds were estimated by the relative frequency of the isomeric NEFA in the fasting human blood [21]. Forty-one out of 47 NEFA fulfilled the quality control criteria that the coefficients of variation (CV) were below 20% for all measurements. Serum NEFA concentrations were calculated as molar percentages of the total NEFA [21]. Enzyme activities were estimated by the following ratios of products to substrates: 18:1/18:0 for stearoyl CoA desaturase-1 (SCD-1), 18:0/16:0 for elongation of very long chain fatty acids protein 6 (EloVL6), and 20:4/20:3 for delta-5-desaturase (Δ -5 D).

Laboratory measurements and calculations. Serum insulin was measured with chemiluminescence technology (CLIA, DiaSorin LIAISON systems, Saluggia, Italy). Glucose concentrations from sodium fluoride plasma were determined using a glucose analyzer (with the glucose oxidase method, Glucose HK Gen.3, Roche Diagnostics, Mannheim, Germany). The following additional laboratory parameters were analyzed: HbA1c (VARIANT II TURBO HbA1c Kit—2.0, Bio-Rad Laboratories, Hercules, USA), hsCRP (wide-range CRP, Siemens AG, Erlangen, Germany), gamma-GT (enzymatic caloric test, Roche Diagnostics), triglycerides (enzymatic caloric test, Roche Diagnostics), cholesterol (enzymatic caloric test, Roche Diagnostics), HDL (enzymatic caloric test, Roche Diagnostics), and LDL was calculated with the Friedewald equation (all triglyceride levels were below 400 mg/dl). The following protein mediators were measured in plasma samples: fetuin-A (ELISA, Bio-Vendor, Heidelberg, Germany), leptin (ELISA "Dual Range", Merck Millipore, Darmstadt, Germany), adiponectin (RIA, Merck Millipore), and resistin (Quantikine ELISA, R&D Systems, Wiesbaden-Nordenstadt, Germany).

The Matsuda Index was calculated as described previously [22] and used to quantify insulin sensitivity. Additionally, the HOMA-IR was assessed as the product of fasting glucose and fasting insulin concentrations, and the adipocyte insulin resistance (Adipocyte-IR) index was calculated as the product of fasting total NEFA_{LC-MS/MS} and fasting insulin concentrations [23, 24]. The disposition index was calculated from the OGTT to measure the relationship between insulin sensitivity and first-phase insulin secretion [25]. The rise in serum insulin during the first 30 minutes of the OGTT was used as a measure of the first-phase insulin secretion. The correlation of this measure with the first-phase secretion in the IVGTT was significantly better than that of the insulinogenic index in a substudy of the PPS-Diab study [15].

Statistical analyses

The statistical analyses were performed with SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). All numeric values are reported as median (first and third quartile) because the majority of the parameters were not normally distributed. Mann-Whitney U tests or a Chi-Square test were used to assess group differences. Multiple comparisons of the NEFA measurements were accounted for by Bonferroni correction. Those significant NEFA measurements from the Mann-Whitney U tests were further analyzed together with clinical parameters as independent variables by binary logistic regression models for the dependent variable pGDM status. The correlations between metric variables were calculated with Spearman's rank correlation coefficients (ρ) with adjustment for BMI or total body fat volume. A p-value <0.05 was considered statistically significant. After Bonferroni correction alpha = 9.62e-4.

Results

Baseline characteristics

We included 62 normoglycemic women after a pregnancy complicated by GDM and 49 controls after a normoglycemic pregnancy in this analysis. The time from delivery to study inclusion was 3–16 months. The baseline characteristics of the study subjects are shown in Table 1. The Matsuda Index of insulin sensitivity and the Disposition Index were lower among the women after GDM (p = 0.030 and p = 0.002, respectively), but the HOMA-IR and the Adipocyte-IR Index were not different between the groups. Although all of the study subjects were normoglycemic, the glucose concentrations were significantly higher at each time point of the OGTT in post-GDM group. Metabolic risk factors such as triglycerides, HDL, hsCRP, gamma-GT, BMI, body fat percentage by bioimpedance measurement and WC were similar in the two groups. In an MRI substudy (n = 62), we also found no significant differences in total body fat volume, abdominal visceral fat volume and liver fat content. The hepatokine fetuin-A was significantly elevated in women after GDM (p = 0.008), but the serum concentrations of the adipokines leptin, adiponectin and resistin were not different (Table 2). There were also no significant differences in macronutrient consumption, as estimated by a food frequency questionnaire (EPIC-FFQ; <u>S1 Table</u>).

Serum NEFA composition in women after GDM and controls

Total fasting NEFA concentrations did not differ between the women after GDM and controls (564.5 μ M (407.0 μ M—668.0 μ M) vs. 548.0 μ M (444.0 μ M—681.0 μ M), <u>Table 3</u>). The

Table 1. Clinical and biochemical characteristics of the study cohort.

	post-GDM	controls	p-value
Clinical characteristics			
Months post-delivery	8.95 (7.50–11.60)	8.80 (7.00–10.30)	0.213
Hormonal contraception n (%)*	7 (11.3)	12 (24.5)	0.067
Age (years)	35 (32–38)	35 (32–37)	0.903
BMI (kg/m²)	23.2 (21.4–26.6)	22.7 (21.3–25.9)	0.297
WC (cm) (n = 58/49) #	78 (73–86)	75 (71–83)	0.247
Waist to hip ratio (n = $58/49$) [#]	0.80 (0.76–0.86)	0.80 (0.75–0.84)	0.277
Body fat _{BIA} (%) (n = 62/48) [#]	29.75 (25.70–37.70)	30.60 (26.20–35.20)	0.861
Systolic blood pressure (mmHg)	119 (112–125)	115 (107–123)	0.063
Diastolic blood pressure (mmHg)	75 (70–79)	72 (64–81)	0.068
Distance (m/d) (n = 41/41) #	6610 (5104–8407)	6838 (5114–8259)	0.597
MRI substudy (n = 37/25) [#]			
Total fat _{MRI} (I)	20.25 (16.46–29.40)	19.65 (16.88–24.26)	0.571
Visceral fat _{MRI} ^a (I)	1.68 (1.13–2.84)	1.34 (1.01–1.91)	0.134
Subcutaneous fat _{MRI} ^a (I)	5.73 (4.12-8.29)	5.61 (4.31–6.72)	0.605
Liver fat (%)	0.51 (0.18–1.27)	0.41 (0.09–0.66)	0.137
Biochemical characteristics			
Matsuda Index	5.35 (3.68-8.02)	6.67 (4.84–8.51)	0.030
HOMA-IR	1.44 (0.94–2.35)	1.22 (0.81–1.91)	0.148
Adipocyte-IR Index ^b	3353 (1760–5496)	2901 (1911–4116)	0.290
Disposition Index	235.67 (176.73–303.60)	303.21 (244.65–368.26)	0.002
Fasting plasma glucose (mg/dl)	91 (87–95)	90 (83–92)	0.026
30min. plasma glucose (mg/dl)	151 (129–170)	140 (121–154)	0.016
60min. plasma glucose (mg/dl)	137 (113–163)	117 (99–132)	0.001
90min. plasma glucose (mg/dl)	111 (97–136)	100 (89–113)	0.005
2 hour plasma glucose (mg/dl)	112 (96–120)	94 (82–110)	<0.001
Triglyceride (mg/dl)	65 (51–89)	63 (50–87)	0.955
HDL (mg/dl)	64 (51–72)	64 (57–74)	0.570
LDL (mg/dl)	104 (89–115)	108 (97–123)	0.057
hsCRP (mg/dl)	0.06 (0.02–0.32)	0.04 (0.01–0.11)	0.252
Gamma-GT (U/I)	14 (12–19)	14 (11–18)	0.858
HbA1c (%)	5.4 (5.3–5.6)	5.3 (5.1–5.5)	0.033
HbA1c (mmol/mol)	35.5 (34.4–37.7)	34.4 (32.2–36.6)	0.033

The values are represented as the medians with interquartile ranges. If not stated otherwise n = 62 for the cases and n = 49 for the controls.

*Chi-Square test.

[#](n = cases/controls).

^aabdominal.

^bAdipocyte-IR Index = fasting total NEFA_{LC-MS/MS} (μM) * fasting insulin (μU/mI).

doi:10.1371/journal.pone.0128001.t001

enzymatic measurement of serum NEFA and the calculated sum of all NEFA species as quantified by LC-MS/MS produced similar results ($\rho = 0.86$, p<0.001).

We were able to quantify 41 NEFA species by LC-MS/MS (<u>Table 3</u>). Monounsaturated fatty acids (MUFA) (46.4% (44.2%–47.8%) were predominantly present in fasting serum followed by SFA (39.5% (37.9%–40.8%) and PUFA (13.8% (13.0%–15.0%). The most abundant NEFA species were oleic acid (18:1 n-9), palmitic acid (16:0), linoleic acid (18:2 n-6) and stearic acid (18:0).

	post-GDM	controls	p-value
Fetuin-A (µg/ml)	288.35 (266.60–312.00)	263.40 (242.20–295.40)	0.008
Leptin (ng/ml)	8.73 (5.07–13.68)	6.89 (2.93–11.56)	0.071
Adiponectin (µg/ml)	9.99 (7.71–16.37)	11.63 (9.32–14.61)	0.512
Resistin (ng/ml)	8.52 (7.18–10.65)	8.90 (7.54–10.86)	0.845

Table 2.	Plasma concentrations of selected biomarkers.
----------	---

The values are represented as the medians with interquartile ranges.

doi:10.1371/journal.pone.0128001.t002

At an exploratory level of significance (p<0.05) we found the following differences in the molar percentages of the various NEFA species in the post-GDM group compared to the controls: 12:0, 14:0, 16:0, 18:0, 26:0, and total SFA were reduced, and 18:1, 18:2, MUFA, total n-6 NEFA and the proportion of total n-6/n-3 NEFA were increased (<u>Table 3, Fig 1</u>). Cases also showed a higher calculated SCD-1 activity (4.70 vs. 4.21, p = 0.010, <u>Table 3</u>), but no changes in EloVL6 or Δ -5 D activities. All differences remained significant with adjustment for BMI and HbA1c, except for 12:0 and 26:0.

After Bonferroni correction for multiple testing, only total SFA were still significantly different between women after GDM and controls (38.6% vs. 40.3%, p = 0.0002). Total serum SFA were unrelated to the daily dietary intake of these fatty acids estimated from the EPIC-FFQ (<u>S2</u> <u>Table</u>). We also did not observe a significant correlation with BMI, but found a negative association between SFA and estimated SCD-1 activity ($\rho = -0.80$, p<0.001).

Associations of NEFA species with body composition and insulin resistance

We examined the associations between the different NEFA species and clinical parameters of body composition (BMI, WC) as well as total body fat and abdominal visceral adipose tissue from the MRI substudy. The group of women after GDM and the control group were combined for this analysis. All NEFA species with at least one association with a Spearman $\rho \ge 0.3$ are shown in Table 4. 16:3, 18:2, 22:4, 26:2 and 26:3 were positively associated with BMI and all other parameters of body fat, whereas 12:0, 14:0, 15:0, 20:0, 15:1, and 20:1 showed negative correlations. With respect to visceral adipose tissue, 14:0 and partially 12:0 remained significantly and inversely associated with WC and abdominal visceral adiposity after adjustment for BMI and total body fat, respectively (Table 4). The associations of NEFA species with measures of adiposity were similar in women after GDM and controls, when we repeated the analyses separately in the two groups (data not shown). We observed no relevant correlations with a Spearman $\rho \ge 0.3$ of single NEFA species and insulin sensitivity (Matsuda Index).

Associations of essential fatty acids with dietary intake

Linoleic acid (18:2 n-6) and linolenic acid (18:3 n-3) are the only two fatty acids that cannot be synthesized endogenously. Over the whole study cohort, dietary intakes of 18:2 and 18:3 correlated with plasma levels of these fatty acids ($\rho = 0.33$, p = 0.002 and $\rho = 0.23$, p = 0.029, respectively). Furthermore, the sum of serum PUFA correlated with estimated PUFA intake (g/day) ($\rho = 0.36$, p = 0.001, <u>S2 Table</u>).

Discussion

The main findings of this study are that in the fasting state the total serum NEFA concentration was similar in normoglycemic women with recent GDM and controls, but that differences

Table 3. Fasting serum NEFA profiles and total NEFA concentrations.

120 0.744% (0.58%-0.90%) 0.80% (0.72%+0.10%) 0.068 0.059 131 0.047% (0.034%-0.95%) 0.34% (0.039%-0.058%) 0.525 141 0.617% (0.51%-0.72%) 0.049% (0.039%-0.75%) 0.913 142 0.051% (0.56%) 0.049% (0.03%)-0.75%) 0.23 150 0.449% (0.04%-0.05%) 0.542% (0.43%-0.05%) 0.23 151 0.043% (0.05%) 0.047% (0.03%-0.05%) 0.23 1561 0.045% (0.05%-0.07%) 0.014 0.004 151 0.045% (0.05%-0.07%) 0.017 0.23 1562 0.074% (0.05%-0.07%) 0.016% (0.028%-0.025%) 0.72 1563 0.026% (0.028%-0.027%) 0.034 0.033 1563 0.026% (0.028%-0.027%) 0.034 0.033 157 0.026% (0.028%-0.027%) 0.034 0.033 158 8.4827 1.036% (1.410%-0.826%) 0.046 0.019 151 0.457% (0.827%-0.25%) 0.041 0.037 152 1.056% (0.168%-0.027%) 0.036% (0.028%-0.027%) 0.057		post-GDM	controls	p-value*	BMI and HbA1c adj. p-value**
13.1 0.047% (0.034%-0.065%) 0.048% (0.039%-0.059%) 0.628 14.0 0.057% (0.518%-0.720%) 0.607% (0.519%-0.755%) 0.513 14.1 0.617% (0.518%-0.720%) 0.649% (0.043%-0.057%) 0.332 15.1 0.045% (0.428%-0.559%) 0.542% (0.457%-0.598%) 0.538 15.1 0.045% (0.028%-0.057%) 0.561% (0.757%-0.578%) 0.623 16.1 5.338% (4.519%-6.021%) 4.982% (4.210%-5.781%) 0.230 16.2 0.074% (0.026%-0.01%) 0.027% (0.022%-0.01%) 0.273 16.3 0.028% (0.022%-0.021%) 0.273	12:0	0.744% (0.595%-0.902%)	0.809% (0.720%-1.018%)	0.008	0.059
141 0.013% (2.94%-3.45%) 0.34% (2.79%-0.75%) 0.913 141 0.617% (0.94%-0.026%) 0.647% (0.04%-0.05%) 0.322 150 0.449% (0.03%-0.05%) 0.642% (0.45%-0.05%) 0.338 151 0.043% (0.03%-0.05%) 0.542% (0.45%-0.05%) 0.338 161 5.338% (0.45%) 0.561% (2.47%-0.534%) 0.230 162 0.074% (0.06%-0.07%) 0.718 0.237 163 0.263% (0.22%-0.01%) 0.265% (0.50%-0.05%) 0.202 171 0.537% (0.32%-0.37%) 0.342% (0.32%-0.01%) 0.202 171 0.357% (0.32%-0.37%) 0.342% (0.32%-0.03%) 0.054 0.033 180 0.484% (0.32%-0.17%) 0.366% (0.75%-0.05%) 0.040 0.019 181 9.485% (0.22%-0.17%) 0.401% (0.865%-11.32%) 0.34 0.033 182 11.065% (0.23%-12.172%) 1.041% (0.865%-11.32%) 0.34 0.019 182 0.156% (0.24%-0.05%) 0.058 0.051% 0.174 184 0.055% (0.04%-0.05%) 0.058% (0.04%-0.05%) 0.056 0.174 182 0.156% (0.256% 0.04%) 0.056% (0.04%-0.05%)	13:1	0.047% (0.034%-0.056%)	0.048% (0.039%-0.059%)	0.525	
14.1 0.617% (0.519%-0.726%) 0.607% (0.519%-0.758%) 0.312 14.2 0.051% (0.436%-0.065%) 0.542% (0.457%-0.558%) 0.323 15.1 0.0435% (0.426%-0.569%) 0.542% (0.457%-0.569%) 0.538 15.1 0.0435% (0.225%-0.01%) 0.964% (0.028%-0.052%) 0.373 16.2 0.074% (0.066%-0.079%) 0.074% (0.022%-0.029%) 0.223 16.3 0.025% (0.427%-0.031%) 0.026% (0.022%-0.029%) 0.273 17.0 0.522% (0.473%-0.531%) 0.036% (3.032%-0.394%) 0.553 17.1 0.357% (0.323%-0.391%) 0.365% (3.032%-0.394%) 0.034 0.019 18.1 3.9483% (3.227%-0.101%) 30.066% (37.322%-40.055%) 0.004 0.019 18.2 1.105% (10.236%-12.172%) 1.041% (9.465%-11.326%) 0.034 0.019 18.3 1.177% (1.031%-3.45%) 1.145% (1.071%-1.322%) 0.044 0.019 18.4 0.055% (0.047%-0.057%) 0.058% (0.046%-0.057%) 0.366 0.019 19.0 0.056% (0.047%-0.055%) 0.056% (0.047%-0.057%) 0.367 0.411 0.415% (1.71%-1.345%) 0.368 0.077 0.222 0.057% (0.046%-0.057%)	14:0	3.013% (2.584%-3.457%)	3.346% (2.779%-3.775%)	0.034	0.030
14:2 0.051% (0.043%-0.057%) 0.049% (0.043%-0.057%) 0.28 15:0 0.495% (0.038%-0.051%) 0.046% (0.038%-0.052%) 0.53 16:0 25.112% (23.393%-25.857%) 25.515% (24.757%-26.314%) 0.29 16:1 5.338 (4.519%-6.051%) 0.928% (24.10%-571%) 0.230 16:2 0.074% (0.068%-0.079%) 0.071% (0.062%-0.019%) 0.723 16:3 0.026% (0.022%-0.031%) 0.26% (0.022%-0.039%) 0.262 17:1 0.577% (0.323%-0.37%) 0.342% (0.320%-0.394%) 0.533 18:0 8.482% (7.644%-9.421%) 9.049% (3.41%-9.455%) 0.040 0.019 18:1 39.483% (38.272%-41.091%) 39.069% (3.7.352%-40.055%) 0.040 0.019 18:2 1.105% (10.23%-10.21%) 1.041% (0.468%-0.057%) 0.034 0.019 18:2 1.055% (0.048%-0.057%) 0.360	14:1	0.617% (0.516%-0.720%)	0.607% (0.519%-0.755%)	0.913	
15:0 0.495% (0.486%-0.596%) 0.542% (0.457%-0.595%) 0.558 15:1 0.043% (0.036%-0.51%) 0.064% (0.038%-0.52%) 0.558 16:0 25.112% (23.936%-25.87%) 25.615% (24.75%-26.31%) 0.004 0.004 16:1 5.338% (4.519%-6.021%) 4.982% (2.10%-5.781%) 0.237 16:2 0.074% (0.025%-0.031%) 0.026% (0.022%-0.029%) 0.723 17:0 0.522% (0.473%-0.61%) 0.026% (0.022%-0.029%) 0.723 17:1 0.357% (0.323%-0.337%) 0.342% (0.320%-0.344%) 0.553 18:0 8.482% (7.644%-9.42%) 9.096% (0.7328%-40.055%) 0.040 0.019 18:1 39.483% (38.272%-41.01%) 39.069% (0.7328%-40.055%) 0.041 0.0133 18:2 1.075% (10.31%-1.345%) 1.145% (10.71%-1.325%) 0.041 0.019 18:3 1.777% (10.31%-1.345%) 1.041% (9.668%-11.325%) 0.654 0.050% (0.044%-0.057%) 0.053% (0.046%-0.057%) 0.360 19:1 0.136% (0.27%-0.056%) 0.054% (0.07%-0.07%) 0.373 20:2 0.05% (0.044%-0.057%) 0.654% (0.037%-0.057%) 0.517 20:1 0.344% (0.313%-0.327%)<	14:2	0.051% (0.043%-0.065%)	0.049% (0.043%-0.057%)	0.392	
15.1 0.043% (0.038%-0.051%) 0.046% (0.038%-0.052%) 0.511 16.0 25.112% (23.938%-25.857%) 25.615% (24.757%-26.314%) 0.014 0.004 16.2 0.074% (0.086%-0.07%) 0.071% (0.082%-0.081%) 0.373 16.3 0.026% (0.022%-0.029%) 0.202 17.0 0.522% (0.473%-0.581%) 0.565% (0.507%-0.590%) 0.202 17.1 0.357% (0.323%-0.37%) 0.342% (0.320%-0.384%) 0.533 18.1 39.433% (0.827%-41.091%) 30.069% (37.352%-40.055%) 0.034 0.019 18.2 11.065% (10.238%-12.172%) 10.401% (0.865%) 10.77	15:0	0.495% (0.426%-0.596%)	0.542% (0.457%-0.598%)	0.238	
16:0 25, 112% (23, 393%-25, 85%) 26, 615% (24, 757%-26, 314%) 0, 14 0.004 16:1 5, 338% (4, 519%-6, 021%) 4, 982% (4, 210%-5, 781%) 0, 230 16:2 0.074% (0, 065%-0, 007%) 0.027% (0, 022%-0, 031%) 0, 202 17:0 0.525% (0, 472%-0, 638%) 0, 202 17:1 0.357% (0, 323%-0, 387%) 0, 342% (0, 320%-0, 394%) 0, 553 18:0 8, 482% (7, 664%-9, 242%) 9, 308% (8, 410%-8, 865%) 0, 040 0, 019 18:1 13, 943% (8, 227% + 40, 61%) 30, 698% (37, 325%-40, 055%) 0, 0404 0, 019 18:2 11, 065% (10, 236% + 12, 172%) 10, 401% (9, 865% + 11, 325%) 0, 634 0, 019 18:3 1, 177% (1, 031% - 1, 345%) 1, 145% (1, 071% - 1, 322%) 0, 614 0, 019 18:4 0, 025% (0, 044% - 0, 057%) 0, 628 0, 608 0, 607 20:0 0, 045% (0, 012% - 0, 045%) 0, 638 0, 607 0, 608 20:1 0, 349% (0, 013% - 0, 028%) 0, 638 0, 607 0, 608 20:2 0, 138% (0, 168% - 0, 028%) 0, 608 0,	15:1	0.043% (0.036%-0.051%)	0.046% (0.038%-0.052%)	0.538	
16:1 5.33% (4.19%-6.021%) 4.962% (4.210%-5.71%) 0.23 16:2 0.074% (0.066%-0.07%) 0.071% (0.062%-0.02%) 0.223 17:0 0.52% (0.473%-0.581%) 0.55% (0.50%-0.59%) 0.523 17:1 0.357% (0.32%-0.397%) 0.342% (0.32%-0.394%) 0.553 18:0 8.482% (7.64%-9.42%) 9.03% (4.10%-9.865%) 0.034 0.033 18:1 39.485% (0.236%-0.27%) 0.044 0.019 18:2 11.055% (10.236%-12.172%) 10.401% (9.865%-0.132%) 0.041 18:4 0.025% (0.019%-0.032%) 0.263% (0.024%-0.055%) 0.441 18:4 0.025% (0.024%-0.067%) 0.360	16:0	25.112% (23.938%-25.857%)	25.615% (24.757%-26.314%)	0.014	0.004
16:2 0.074% (0.068%-0.079%) 0.071% (0.062%-0.029%) 0.723 16:3 0.026% (0.022%-0.029%) 0.723 17:0 0.525% (0.473%-0.581%) 0.555% (0.570%-0.590%) 0.202 17:1 0.357% (0.223%-0.387%) 0.342% (0.320%-0.394%) 0.553 18:0 8.442% (7.644%-9.242%) 9.33% (8.410%-8.855%) 0.040 0.019 18:1 3.943% (8.272%-4.1041%) 3.049% (3.732%-4.0055%) 0.404 0.019 18:2 11.065% (10.236%-12.172%) 10.401% (3.865%-11.326%) 0.034 0.019 18:3 1.177% (1.031%-1.345%) 1.145% (1.071%-1.322%) 0.941 18:4 0.025% (0.044%-0.057%) 0.053% (0.046%-0.057%) 0.360 19:1 0.136% (0.127%-0.150%) 0.053% (0.046%-0.057%) 0.517 20:0 0.055% (0.044%-0.068%) 0.058 0.0517 20:1 0.349% (0.317%-0.398%) 0.344% (0.168%-0.21%) 0.69 20:2 0.074% (0.068%-0.228%) 0.931 0.228 20:3 0.216% (0.187%-0.238%) 0.950 0.223 22:4 0.068% (0.074%-0.11%) 0.068 0.031 22:4	16:1	5.338% (4.519%-6.021%)	4.982% (4.210%-5.781%)	0.230	
16:3 0.028% (0.023% 0.023% (0.023% (0.023% (0.029%)) 0.723 17:0 0.552% (0.473% 0.051%) 0.555% (0.507% 0.509%) 0.522 17:0 0.557% (0.323% 0.387%) 0.342% (0.320% 0.39%) 0.034 18:0 8.482% (7.664% 0.242%) 9.036% (0.410% 0.965%) 0.040 0.033 18:1 39.483% (38.272% 41.091%) 39.069% (7.352% 40.055%) 0.040 0.019 18:2 1.065% (0.296% 12.172%) 10.411% (0.665% 11.322%) 0.941 18:3 1.177% (1.031% 1.345%) 1.145% (1.071% 1.322%) 0.941 18:4 0.025% (0.019% 0.032%) 0.053% (0.046% 0.057%) 0.360 19:1 0.166% (0.127% 0.150%) 0.143% (0.155%) 0.658 20:0 0.055% (0.048% 0.056%) 0.745% (0.51% 0.07%) 0.517 20:1 0.446% (0.317% 0.338%) 0.244% (0.313% 0.337% 0.37%) 0.517 20:2 0.144% (0.169% 0.216%) 0.738 0.517 20:3 0.215% (0.189% 0.228%) 0.274% (0.617% 0.092%) 0.517 20:4 0.666% (0.616% 0.935%) 0.774% (0.616% 0.228%) 0.339 21:2 0.007% (0.006% 0.008%) 0.0278 (0.001% 0.009%) <t< td=""><td>16:2</td><td>0.074% (0.066%-0.079%)</td><td>0.071% (0.062%-0.081%)</td><td>0.373</td><td></td></t<>	16:2	0.074% (0.066%-0.079%)	0.071% (0.062%-0.081%)	0.373	
17.0 0.522% (0.473%-0.581%) 0.557% (0.507%-0.590%) 0.202 17.1 0.357% (0.323%-0.387%) 0.342% (0.320%-0.394%) 0.033 18:0 8.48% (7.664%-8.242%) 0.903% (34.10%-8.865%) 0.040 0.019 18:1 39.483% (38.272%-41.091%) 39.069% (37.352%-40.055%) 0.040 0.019 18:2 11.065% (10.26%+12.172%) 10.401% (9.865%+11.326%) 0.941 18:3 1.177% (1.031%-1.345%) 1.145% (1.071%-1.322%) 0.941 18:4 0.025% (0.044%-0.057%) 0.053% (0.046%-0.057%) 0.360 19:0 0.555% (0.048%-0.068%) 0.055% (0.046%-0.077%) 0.127 20:1 0.494% (0.169%-0.216%) 0.141% (0.158%-0.157%) 0.517 20:2 0.194% (0.169%-0.216%) 0.183% (0.168%-0.237%) 0.517 20:3 0.215% (0.187%-0.234%) 0.208% (0.174%-0.322%) 0.931 20:4 0.766% (0.077%-0.24%) 0.74% (0.61%-0.237%) 0.517 20:2 0.077% (0.069%-0.01%) 0.239 223 21:3 0.216% (0.077%-0.027%) 0.027% (0.069%-0.07%) 0.239 22:4 0.066% (0.077%-0.097%) 0.016% (0.078%-0.07%) <td>16:3</td> <td>0.026% (0.022%-0.031%)</td> <td>0.026% (0.022%-0.029%)</td> <td>0.723</td> <td></td>	16:3	0.026% (0.022%-0.031%)	0.026% (0.022%-0.029%)	0.723	
17:1 0.357% (0.323%-0.387%) 0.342% (0.320%-0.394%) 0.553 18:0 8.482% (7.664%-6.242%) 9.036% (8.410%-6.965%) 0.004 0.033 18:1 39.438% (8.272%+41.091%) 39.069% (5.3282%-40.65%) 0.004 0.019 18:2 11.065% (10.236%+12.172%) 10.401% (9.865%+11.326%) 0.034 0.019 18:3 1.177% (1.031%-1.345%) 1.145% (1.071%-1.322%) 0.941 18:4 0.025% (0.019%-0.032%) 0.026% (0.048%-0.065%) 0.368 19:0 0.505% (0.048%-0.057%) 0.365% (0.064%-0.057%) 0.360 19:1 0.168% (0.127%-0.150%) 0.414% (0.138%-0.155%) 0.658 20:0 0.055% (0.048%-0.068%) 0.054% (0.051%-0.070%) 0.127 20:1 0.494% (0.117%-0.328%) 0.248% (0.317%-0.327%) 0.517 20:2 0.194% (0.169%-0.216%) 0.183% (0.166%-0.07%) 0.517 20:2 0.194% (0.169%-0.216%) 0.027% (0.027%-0.108%) 0.739 21:2 0.066% (0.610% -0.007%) 0.239 0.228 22:4 0.066% (0.077% -0.022%) 0.281 0.228 22:4 0.066% (0.007% -0.075%) 0.021	17:0	0.522% (0.473%-0.581%)	0.555% (0.507%-0.590%)	0.202	
18:0 8.482% (7.664%-9.242%) 9.036% (8.410%-9.665%) 0.034 0.033 18:1 39.485% (38.272%-41.091%) 39.069% (37.352%-40.055%) 0.040 0.019 18:2 11.065% (10.268% (1.272%) 10.401% (9.665% (1.222%) 0.941 18:3 1.177% (1.031%-1.345%) 1.145% (1.071%-1.322%) 0.941 18:4 0.025% (0.049%-0.057%) 0.055% (0.046%-0.057%) 0.658 19:1 0.136% (0.127%-0.150%) 0.058% (0.046%-0.057%) 0.658 20:0 0.055% (0.049%-0.067%) 0.617% 0.669 20:1 0.349% (0.317%-0.398%) 0.244% (0.158%-0.270%) 0.127 20:1 0.349% (0.167%-0.234%) 0.206% (0.74%-0.108%) 0.517 20:2 0.145% (0.169%-0.216%) 0.163%-0.232%) 0.931 20:3 0.215% (0.167%-0.234%) 0.206% (0.74%-0.108%) 0.739 22:2 0.007% (0.006%-0.011%) 0.009% (0.011%) 0.956 22:3 0.109% (0.009%-0.011%) 0.010% (0.009%-0.011%) 0.890 22:4 0.066% (0.077%-0.007%) 0.261 22:5 0.180% (0.163%-0.202%) 0.616 2239 24:4	17:1	0.357% (0.323%-0.387%)	0.342% (0.320%-0.394%)	0.553	
18:1 39.483% (38.272%-41.091%) 39.069% (37.352%-40.055%) 0.040 0.019 18:2 11.065% (10.236%-12.172%) 10.401% (9.665%+11.326%) 0.034 0.019 18:3 1.177% (10.31%-1.345%) 1.145% (10.71%-1.222%) 0.941 19:4 0.025% (0.019%-0.032%) 0.025% (0.044%-0.036%) 0.077 19:0 0.055% (0.044%-0.057%) 0.155% 0.658 20:0 0.055% (0.045%-0.068%) 0.058% (0.051%-0.070%) 0.127 20:1 0.349% (0.317%-0.398%) 0.344% (0.313%-0.387%) 0.517 20:2 0.155% (0.167%-0.24%) 0.208% (0.0168%-0.201%) 0.695 20:3 0.215% (0.167%-0.324%) 0.209% (0.074%-0.108%) 0.739 22:4 0.606% (0.075%-0.049%) 0.090% (0.074%-0.108%) 0.739 22:4 0.066% (0.075%-0.049%) 0.016% (0.099%-0.011%) 0.899 22:4 0.066% (0.075%-0.049%) 0.016% (0.099%-0.011%) 0.899 22:4 0.066% (0.075%-0.014%) 0.016% (0.026%-0.007%) 0.617 24:4 0.066% (0.025%-0.014%) 0.041% (0.345%-0.53%) 0.515 24:4 0.066% (0.024%-0.026%) 0.026% (0.026%-0	18:0	8.482% (7.664%-9.242%)	9.036% (8.410%-9.865%)	0.034	0.033
18:2 11.065% (10.236%-12.172%) 10.401% (9.865%-11.326%) 0.034 0.019 18:3 1.177% (1.031%-1.345%) 1.145% (1.071%-1.322%) 0.941 18:4 0.025% (0.019%-0.032%) 0.028% (0.024%-0.057%) 0.360 19:0 0.050% (0.044%-0.057%) 0.155% (0.064%-0.057%) 0.568 20:0 0.055% (0.046%-0.057%) 0.127 20:1 0.349% (0.317%-0.398%) 0.344% (0.313%-0.387%) 0.517 20:2 0.144% (0.169%-0.216%) 0.183% (0.166%-0.201%) 0.669 20:3 0.215% (0.061%-0.935%) 0.774% (0.617%-0.332%) 0.931 20:4 0.760% (0.616%-0.935%) 0.774% (0.617%-0.932%) 0.950 22:2 0.007% (0.066%-0.008%) 0.007% (0.066%-0.007%) 0.239 22:3 0.010% (0.069%-0.01%) 0.010% (0.098%-0.01%) 0.880 22:4 0.866% (0.077%-0.97%) 0.81% (0.74%-0.040%) 0.766 22:5 0.180% (0.163%-0.202%) 0.081% (0.074%-0.040%) 0.766 22:6 0.415% (0.359%-0.511%) 0.441% (0.345%-0.537%) 0.515 24:0 0.026% (0.005%-0.007%) 0.0262 24:1 0.044% (0.034%-0.049%)	18:1	39.483% (38.272%-41.091%)	39.069% (37.352%-40.055%)	0.040	0.019
18:3 1.177% (1.031%-1.345%) 1.145% (1.071%-1.322%) 0.941 18:4 0.025% (0.049%-0.057%) 0.025% (0.024%-0.036%) 0.077 19:0 0.150% (0.044%-0.057%) 0.053% (0.046%-0.057%) 0.360 19:1 0.136% (0.127%-0.150%) 0.053% (0.045%-0.057%) 0.568 20:0 0.055% (0.048%-0.089%) 0.054% (0.155%) 0.517 20:1 0.349% (0.317%-0.398%) 0.344% (0.138%-0.327%) 0.517 20:2 0.144% (0.169%-0.218%) 0.208% (0.168%-0.232%) 0.931 20:4 0.760% (0.616%-0.335%) 0.774% (0.617%-0.332%) 0.950 20:5 0.899% (0.071%-0.114%) 0.090% (0.078%-0.078%) 0.239 22:2 0.007% (0.066%-0.008%) 0.007% (0.069%-0.01%) 0.890 22:3 0.101% (0.009%-0.011%) 0.890 22:4 0.898% (0.071%-0.97%) 0.081% (0.074%-0.091%) 0.866 22:5 0.160% (0.163%-0.202%) 0.163% (0.164%-0.204%) 0.767 24:4 0.066% (0.009%) 0.027% (0.021%-0.032%) 0.262 24:5 0.161% (0.135%-0.051%) 0.414% (0.345%-0.537%) 0.515 24:6 0.026% (18:2	11.065% (10.236%-12.172%)	10.401% (9.865%-11.326%)	0.034	0.019
18:4 0.025% (0.019%-0.032%) 0.028% (0.024%-0.036%) 0.077 19:0 0.050% (0.044%-0.067%) 0.053% (0.046%-0.057%) 0.360 19:1 0.136% (0.127%-0.150%) 0.141% (0.126%-0.155%) 0.658 20:0 0.055% (0.046%-0.068%) 0.056% (0.057%) 0.127 20:1 0.349% (0.317%-0.398%) 0.344% (0.313%-0.387%) 0.517 20:2 0.194% (0.169%-0.216%) 0.183% (0.166%-0.203%) 0.931 20:3 0.215% (0.161%-0.234%) 0.206% (0.68%-0.023%) 0.950 20:4 0.760% (0.616%-0.935%) 0.774% (0.617%-0.932%) 0.950 20:5 0.089% (0.071%-0.114%) 0.909% (0.074%-0.108%) 0.739 22:2 0.007% (0.006%-0.008%) 0.007% (0.006%-0.007%) 0.289 22:3 0.010% (0.009%-0.011%) 0.016% (0.007%-0.007%) 0.262 22:4 0.868% (0.077%-0.097%) 0.81% (0.21%-0.032%) 0.262 22:5 0.180% (0.163%-0.202%) 0.183% (0.164%-0.204%) 0.766 22:4 0.086% (0.007%-0.008%) 0.027% (0.021%-0.032%) 0.262 24:1 0.041% (0.334%-0.047%) 0.677 24:2 0.	18:3	1.177% (1.031%-1.345%)	1.145% (1.071%-1.322%)	0.941	
19:0 0.050% (0.044%-0.057%) 0.053% (0.046%-0.057%) 0.360 19:1 0.136% (0.127%-0.150%) 0.141% (0.128%-0.155%) 0.658 20:0 0.055% (0.048%-0.068%) 0.054% (0.031%-0.070%) 0.127 20:1 0.349% (0.317%-0.398%) 0.344% (0.313%-0.387%) 0.517 20:2 0.194% (0.169%-0.216%) 0.183% (0.166%-0.232%) 0.931 20:4 0.760% (0.616%-0.935%) 0.774% (0.617%-0.138%) 0.739 22:2 0.007% (0.066%-0.008%) 0.007% (0.006%-0.007%) 0.239 22:3 0.017% (0.009%-0.011%) 0.01% (0.009%-0.011%) 0.889 22:4 0.866% (0.077%-0.997%) 0.81% (0.071%-0.011%) 0.889 22:5 0.180% (0.163%-0.202%) 0.183% (0.164%-0.204%) 0.766 22:4 0.866% (0.077%-0.097%) 0.81% (0.071%-0.01%) 0.819 22:4 0.866% (0.077%-0.097%) 0.81% (0.021%-0.024%) 0.766 22:4 0.866% (0.075%-0.006%) 0.027% (0.021%-0.024%) 0.766 24:4 0.024% (0.024%-0.046%) 0.041% (0.345%-0.537%) 0.515 24:4 0.025% (0.005%-0.007%) 0.677 243 0.002% (0.005%-0.	18:4	0.025% (0.019%-0.032%)	0.028% (0.024%-0.036%)	0.077	
19:1 0.136% (0.127%-0.150%) 0.141% (0.126%-0.155%) 0.658 20:0 0.055% (0.048%-0.068%) 0.058% (0.051%-0.070%) 0.127 20:1 0.349% (0.317%-0.398%) 0.344% (0.313%-0.387%) 0.517 20:2 0.194% (0.169%-0.216%) 0.183% (0.166%-0.201%) 0.069 20:3 0.215% (0.187%-0.234%) 0.208% (0.074%-0.232%) 0.950 20:4 0.760% (0.616%-0.935%) 0.774% (0.617%-0.932%) 0.950 20:5 0.099% (0.071%-0.114%) 0.090% (0.074%-0.108%) 0.739 22:2 0.007% (0.006%-0.008%) 0.007% (0.006%-0.007%) 0.239 22:3 0.010% (0.009%-0.011%) 0.980 0.880 22:4 0.0866% (0.077%-0.097%) 0.081% (0.071%-0.091%) 0.880 22:5 0.180% (0.163%-0.202%) 0.183% (0.164%-0.204%) 0.766 22:6 0.415% (0.359%-0.511%) 0.441% (0.345%-0.537%) 0.515 24:1 0.041% (0.034%-0.049%) 0.040% (0.034%-0.047%) 0.677 24:3 0.002% (0.001%-0.002%) 0.442 244 0.005% (0.005%-0.006%) 0.002% (0.004%-0.005%) 0.071 24:4 0.005% (0.005%-0.006%)	19:0	0.050% (0.044%-0.057%)	0.053% (0.046%-0.057%)	0.360	
20:0 0.055% (0.048%-0.068%) 0.058% (0.051%-0.070%) 0.127 20:1 0.349% (0.317%-0.398%) 0.344% (0.313%-0.387%) 0.517 20:2 0.149% (0.169%-0.216%) 0.168% (0.166%-0.232%) 0.931 20:3 0.215% (0.167%-0.234%) 0.208% (0.168%-0.232%) 0.931 20:4 0.760% (0.616%-0.935%) 0.774% (0.617%-0.932%) 0.950 20:5 0.089% (0.071%-0.114%) 0.090% (0.074%-0.108%) 0.739 22:2 0.007% (0.006%-0.008%) 0.007% (0.006%-0.007%) 0.239 22:3 0.0107% (0.009%-0.011%) 0.81% (0.071%-0.091%) 0.880 22:4 0.066% (0.077%-0.097%) 0.81% (0.071%-0.091%) 0.086 22:5 0.180% (0.163%-0.202%) 0.182 0.016 22:6 0.415% (0.359%-0.511%) 0.441% (0.345%-0.537%) 0.515 24:0 0.024% (0.021%-0.030%) 0.027% (0.021%-0.032%) 0.262 24:1 0.041% (0.034%-0.049%) 0.067% (0.005%) 0.074 24:3 0.002% (0.001%-0.002%) 0.0442 0.026% (0.002%-0.004%) 24:4 0.055% (19:1	0.136% (0.127%-0.150%)	0.141% (0.126%-0.155%)	0.658	
20:10.349% (0.317%-0.398%)0.344% (0.313%-0.387%)0.51720:20.194% (0.169%-0.216%)0.183% (0.166%-0.217%)0.06920:30.215% (0.187%-0.234%)0.208% (0.188%-0.232%)0.93120:40.760% (0.616%-0.935%)0.774% (0.617%-0.932%)0.95020:50.089% (0.071%-0.114%)0.090% (0.074%-0.108%)0.73922:20.007% (0.006%-0.008%)0.007% (0.006%-0.007%)0.23922:30.010% (0.009%-0.011%)0.010% (0.009%-0.011%)0.88022:40.086% (0.077%-0.097%)0.81% (0.071%-0.019%)0.68622:50.180% (0.163%-0.202%)0.183% (0.164%-0.204%)0.76622:60.415% (0.359%-0.511%)0.411% (0.345%-0.537%)0.51524:00.024% (0.021%-0.030%)0.027% (0.021%-0.032%)0.26224:10.041% (0.034%-0.049%)0.040% (0.004%-0.005%)0.67724:30.005% (0.001%-0.002%)0.002% (0.001%-0.002%)0.44224:40.005% (0.005%-0.006%)0.005% (0.004%-0.005%)0.7124:50.007% (0.005%-0.006%)0.005% (0.005%-0.007%)0.18026:00.002% (0.002%-0.004%)0.006% (0.005%-0.007%)0.18026:10.005% (0.005%-0.007%)0.006% (0.005%-0.007%)0.90126:20.008% (0.002%-0.004%)0.003% (0.002%-0.004%)0.633SFA38.547% (36.940%-39.937%)40.323% (38.769%-41.630%) 0.001* 40/FA46.655% (45.006%-48.549%)45.972% (43.697%-47.100%)0.01101/FA46.652% (1.733%-2.208%)1.974% (1	20:0	0.055% (0.048%-0.068%)	0.058% (0.051%-0.070%)	0.127	
20.20.194% (0.169%-0.216%)0.183% (0.166%-0.201%)0.06920:30.215% (0.187%-0.234%)0.208% (0.186%-0.232%)0.93120:40.760% (0.616%-0.935%)0.774% (0.617%-0.932%)0.95020:50.089% (0.071%-0.114%)0.090% (0.074%-0.108%)0.73922:20.007% (0.066%-0.008%)0.007% (0.006%-0.007%)0.23922:30.010% (0.009%-0.011%)0.010% (0.009%-0.011%)0.89022:40.866% (0.077%-0.997%)0.81% (0.071%-0.091%)0.86622:50.180% (0.163%-0.202%)0.183% (0.164%-0.204%)0.76622:60.415% (0.359%-0.511%)0.441% (0.345%-0.537%)0.51524:00.024% (0.021%-0.030%)0.027% (0.021%-0.032%)0.67724:30.002% (0.001%-0.002%)0.040% (0.034%-0.047%)0.67724:30.002% (0.005%-0.006%)0.005% (0.006%-0.008%)0.92824:40.005% (0.005%-0.006%)0.006% (0.006%-0.008%)0.92824:50.007% (0.005%-0.006%)0.006% (0.005%-0.007%)0.90124:50.007% (0.002%-0.004%)0.006% (0.005%-0.007%)0.90126:00.002% (0.002%-0.004%)0.006% (0.005%-0.007%)0.90126:10.066% (0.005%-0.007%)0.9010.01426:20.088 (0.007%-0.011%)0.0140.01426:30.003% (0.002%-0.004%)0.6330.00126:20.088 (0.007%-0.011%)0.5170.0010.01426:30.003% (0.002%-0.004%)0.6330.00126:40.059 (0.005%-0.007%)0	20:1	0.349% (0.317%-0.398%)	0.344% (0.313%-0.387%)	0.517	
20:30.215% (0.187%-0.234%)0.208% (0.188%-0.232%)0.93120:40.760% (0.616%-0.935%)0.774% (0.617%-0.932%)0.95020:50.089% (0.071%-0.114%)0.090% (0.074%-0.108%)0.73922:20.007% (0.006%-0.008%)0.007% (0.006%-0.007%)0.23922:30.010% (0.009%-0.011%)0.010% (0.009%-0.011%)0.88022:40.866% (0.077%-0.097%)0.081% (0.071%-0.091%)0.86622:50.180% (0.163%-0.202%)0.183% (0.164%-0.204%)0.76622:60.415% (0.359%-0.511%)0.441% (0.345%-0.537%)0.51524:00.024% (0.021%-0.030%)0.027% (0.021%-0.032%)0.26224:10.041% (0.034%-0.049%)0.040% (0.034%-0.047%)0.67724:30.002% (0.001%-0.002%)0.044224:40.005% (0.005%-0.006%)0.005% (0.006%-0.008%)0.92824:50.007% (0.005%-0.006%)0.006% (0.006%-0.008%)0.92824:60.005% (0.004%-0.006%)0.006% (0.006%-0.007%)0.18026:00.002% (0.001%-0.007%)0.1800.97926:10.006% (0.005%-0.007%)0.90126:20.008% (0.005%-0.007%)0.90126:30.003% (0.002%-0.004%)0.003% (0.002%-0.004%)0.633SFA38.547% (36.940%-39.937%)40.323% (38.769%-41.630%)<0.001#	20:2	0.194% (0.169%-0.216%)	0.183% (0.166%-0.201%)	0.069	
20.40.760% (0.616%-0.935%)0.774% (0.617%-0.932%)0.95020.50.089% (0.071%-0.114%)0.090% (0.074%-0.108%)0.73922.20.007% (0.006%-0.008%)0.007% (0.006%-0.007%)0.23922.30.010% (0.009%-0.011%)0.010% (0.009%-0.011%)0.89022.40.866% (0.077%-0.097%)0.081% (0.071%-0.091%)0.08622.50.180% (0.163%-0.202%)0.183% (0.164%-0.204%)0.76622.60.415% (0.359%-0.511%)0.441% (0.345%-0.537%)0.51524.00.024% (0.021%-0.030%)0.027% (0.021%-0.032%)0.26224.10.041% (0.034%-0.049%)0.040% (0.034%-0.047%)0.67724.30.005% (0.005%-0.006%)0.005% (0.004%-0.005%)0.07124.50.005% (0.005%-0.006%)0.006% (0.006%-0.006%)0.92824.60.005% (0.005%-0.006%)0.006% (0.006%-0.007%)0.18026.00.002% (0.002%-0.004%)0.068% (0.005%-0.007%)0.90126.10.006% (0.005%-0.007%)0.90126.226.30.003% (0.002%-0.004%)0.0480.97926.10.006% (0.005%-0.007%)0.90126.20.008% (0.005%-0.007%)0.90126.30.003% (0.002%-0.004%)0.06327.438.547% (36.940%-39.937%)40.323% (38.769%-41.630%)<0.001#	20:3	0.215% (0.187%-0.234%)	0.208% (0.188%-0.232%)	0.931	
20:50.089% (0.071%-0.114%)0.090% (0.074%-0.108%)0.73922:20.007% (0.006%-0.008%)0.007% (0.006%-0.007%)0.23922:30.010% (0.009%-0.011%)0.010% (0.009%-0.011%)0.89022:40.086% (0.077%-0.097%)0.081% (0.071%-0.091%)0.08622:50.180% (0.163%-0.202%)0.183% (0.164%-0.204%)0.76622:60.415% (0.359%-0.511%)0.441% (0.245%-0.537%)0.51524:00.024% (0.021%-0.030%)0.027% (0.021%-0.032%)0.26224:10.041% (0.034%-0.049%)0.040% (0.034%-0.047%)0.67724:30.002% (0.001%-0.002%)0.002% (0.001%-0.002%)0.44224:40.005% (0.005%-0.006%)0.005% (0.004%-0.05%)0.07124:50.007% (0.005%-0.008%)0.006% (0.005%-0.007%)0.18026:00.002% (0.002%-0.004%)0.003% (0.002%-0.004%)0.04826:10.006% (0.005%-0.007%)0.006% (0.005%-0.007%)0.51726:30.003% (0.002%-0.004%)0.003% (0.002%-0.004%)0.51726:30.003% (0.002%-0.004%)0.003% (0.002%-0.004%)0.633SFA38.547% (38.940%-39.937%)40.323% (38.769%-41.630%)<0.001#	20:4	0.760% (0.616%-0.935%)	0.774% (0.617%-0.932%)	0.950	
22:20.007% (0.006%-0.008%)0.007% (0.006%-0.007%)0.23922:30.010% (0.009%-0.011%)0.010% (0.009%-0.011%)0.89022:40.086% (0.077%-0.097%)0.081% (0.071%-0.091%)0.08622:50.180% (0.163%-0.202%)0.183% (0.164%-0.204%)0.76622:60.415% (0.35%-0.511%)0.441% (0.345%-0.537%)0.51524:00.024% (0.021%-0.030%)0.027% (0.021%-0.032%)0.26224:10.041% (0.034%-0.049%)0.040% (0.034%-0.047%)0.67724:30.002% (0.005%-0.002%)0.002% (0.001%-0.002%)0.44224:40.005% (0.005%-0.006%)0.005% (0.004%-0.005%)0.07124:50.007% (0.005%-0.008%)0.006% (0.005%-0.007%)0.18026:00.002% (0.002%-0.004%)0.003% (0.002%-0.004%)0.04826:10.006% (0.005%-0.007%)0.90126:20.008% (0.007%-0.011%)0.006% (0.005%-0.007%)0.90126:30.003% (0.002%-0.004%)0.003% (0.002%-0.004%)0.633SFA38.547% (36.940%-39.937%)40.323% (38.769%-41.630%)<0.001"	20:5	0.089% (0.071%-0.114%)	0.090% (0.074%-0.108%)	0.739	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	22:2	0.007% (0.006%-0.008%)	0.007% (0.006%-0.007%)	0.239	
22:40.086% (0.077%-0.097%)0.081% (0.071%-0.091%)0.08622:50.180% (0.163%-0.202%)0.183% (0.164%-0.204%)0.76622:60.415% (0.359%-0.511%)0.441% (0.345%-0.537%)0.51524:00.024% (0.021%-0.030%)0.027% (0.021%-0.032%)0.26224:10.041% (0.034%-0.049%)0.040% (0.034%-0.047%)0.67724:30.002% (0.001%-0.002%)0.002% (0.001%-0.002%)0.44224:40.005% (0.005%-0.006%)0.005% (0.004%-0.005%)0.07124:50.007% (0.005%-0.006%)0.006% (0.006%-0.008%)0.92824:60.005% (0.004%-0.006%)0.006% (0.005%-0.007%)0.18026:00.002% (0.002%-0.004%)0.006% (0.005%-0.007%)0.99126:10.006% (0.007%-0.011%)0.006% (0.005%-0.007%)0.99126:20.008% (0.007%-0.011%)0.008% (0.002%-0.004%)0.633SFA38.547% (36.940%-39.937%)40.323% (38.769%-41.630%)<0.001#	22:3	0.010% (0.009%-0.011%)	0.010% (0.009%-0.011%)	0.890	
22:5 $0.180\% (0.163\% - 0.202\%)$ $0.183\% (0.164\% - 0.204\%)$ 0.766 22:6 $0.415\% (0.359\% - 0.511\%)$ $0.441\% (0.345\% - 0.537\%)$ 0.515 24:0 $0.024\% (0.021\% - 0.030\%)$ $0.027\% (0.021\% - 0.032\%)$ 0.262 24:1 $0.041\% (0.034\% - 0.049\%)$ $0.040\% (0.034\% - 0.047\%)$ 0.677 24:3 $0.002\% (0.001\% - 0.002\%)$ $0.002\% (0.001\% - 0.002\%)$ 0.442 24:4 $0.005\% (0.005\% - 0.066\%)$ $0.005\% (0.004\% - 0.005\%)$ 0.071 24:5 $0.007\% (0.005\% - 0.008\%)$ $0.006\% (0.006\% - 0.008\%)$ 0.928 24:6 $0.005\% (0.004\% - 0.006\%)$ $0.006\% (0.005\% - 0.007\%)$ 0.180 26:0 $0.002\% (0.002\% - 0.004\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.991 26:1 $0.006\% (0.005\% - 0.007\%)$ 0.901 0.633 26:2 $0.008\% (0.007\% - 0.011\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.633 SFA $38.547\% (36.940\% - 39.937\%)$ $40.323\% (38.769\% - 41.630\%)$ $<0.001\%$ MUFA $46.655\% (45.006\% - 48.549\%)$ $45.972\% (43.697\% - 47.010\%)$ 0.011 PUFA $14.699\% (13.652\% - 15.906\%)$ $13.974\% (13.295\% - 15.146\%)$ 0.563 $\sum ra3$ $1.952\% (1.733\% - 2.208\%)$ $1.954\% (1.801\% - 2.184\%)$ 0.563 $\sum ra6$ $2.325\% (11.493\% - 13.775\%)$ $11.792\% (11.004\% - 12.841\%)$ 0.033 0.015	22:4	0.086% (0.077%-0.097%)	0.081% (0.071%-0.091%)	0.086	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	22:5	0.180% (0.163%-0.202%)	0.183% (0.164%-0.204%)	0.766	
24:0 $0.024\% (0.021\% - 0.030\%)$ $0.027\% (0.021\% - 0.032\%)$ 0.262 24:1 $0.041\% (0.034\% - 0.049\%)$ $0.040\% (0.034\% - 0.047\%)$ 0.677 24:3 $0.002\% (0.001\% - 0.002\%)$ $0.002\% (0.001\% - 0.002\%)$ 0.442 24:4 $0.005\% (0.005\% - 0.006\%)$ $0.005\% (0.004\% - 0.005\%)$ 0.071 24:5 $0.007\% (0.005\% - 0.008\%)$ $0.006\% (0.006\% - 0.008\%)$ 0.928 24:6 $0.005\% (0.004\% - 0.006\%)$ $0.006\% (0.005\% - 0.007\%)$ 0.180 26:0 $0.002\% (0.002\% - 0.004\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.991 26:1 $0.006\% (0.005\% - 0.007\%)$ $0.006\% (0.005\% - 0.007\%)$ 0.901 26:2 $0.008\% (0.007\% - 0.011\%)$ $0.008\% (0.006\% - 0.011\%)$ 0.517 26:3 $0.003\% (0.002\% - 0.004\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.633 SFA $38.547\% (36.940\% - 39.937\%)$ $40.323\% (38.769\% - 41.630\%)$ $0.001^{#}$ MUFA $46.655\% (45.006\% - 48.549\%)$ $45.972\% (43.697\% - 47.010\%)$ 0.011 PUFA $14.699\% (13.652\% - 15.906\%)$ $13.974\% (13.295\% - 15.146\%)$ 0.563 $\Sigma n-6$ $12.325\% (11.493\% - 13.775\%)$ $11.792\% (11.004\% - 12.841\%)$ 0.033 0.015	22:6	0.415% (0.359%-0.511%)	0.441% (0.345%-0.537%)	0.515	
24:1 $0.041\% (0.034\% - 0.049\%)$ $0.040\% (0.034\% - 0.047\%)$ 0.677 24:3 $0.002\% (0.001\% - 0.002\%)$ $0.002\% (0.001\% - 0.002\%)$ 0.442 24:4 $0.005\% (0.005\% - 0.006\%)$ $0.005\% (0.004\% - 0.005\%)$ 0.071 24:5 $0.007\% (0.005\% - 0.008\%)$ $0.006\% (0.006\% - 0.008\%)$ 0.928 24:6 $0.005\% (0.004\% - 0.006\%)$ $0.006\% (0.005\% - 0.007\%)$ 0.180 26:0 $0.002\% (0.002\% - 0.004\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.048 0.979 26:1 $0.006\% (0.005\% - 0.007\%)$ $0.006\% (0.005\% - 0.007\%)$ 0.901 26:2 $0.008\% (0.007\% - 0.011\%)$ $0.008\% (0.006\% - 0.011\%)$ 0.517 26:3 $0.003\% (0.002\% - 0.004\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.633 SFA $38.547\% (36.940\% - 39.937\%)$ $40.323\% (38.769\% - 41.630\%)$ <0.001 MUFA $46.655\% (45.006\% - 48.549\%)$ $45.972\% (43.697\% - 47.010\%)$ 0.011 PUFA $14.699\% (13.652\% - 15.906\%)$ $13.974\% (13.295\% - 15.146\%)$ 0.563 Σ n-3 $1.952\% (1.733\% - 2.208\%)$ $1.954\% (1.801\% - 2.184\%)$ 0.033 0.015 Σ n-6 $12.325\% (11.493\% - 13.775\%)$ $11.792\% (11.004\% - 12.841\%)$ 0.033 0.015	24:0	0.024% (0.021%-0.030%)	0.027% (0.021%-0.032%)	0.262	
24:3 0.002% 0.001% - 0.002% 0.002% 0.442 24:4 0.005% 0.005% 0.005% 0.001% - 0.005% 0.071 24:5 0.007% 0.005% - 0.008% 0.006% 0.006% 0.928 24:6 0.005% 0.005% 0.006% 0.008% 0.928 26:0 0.002% 0.002% - 0.004% 0.003% 0.0048 0.979 26:1 0.006% 0.005% - 0.007% 0.901 26:2 0.008% 0.007% - 0.011% 0.008% 0.002% - 0.004% 0.517 26:3 0.003% 0.002% - 0.004% 0.003% 0.633 SFA 38.547% $(36.940\%$ - $39.937\%)$ 40.323% $(38.769\%$ - $41.630\%)$ <0.001 #MUFA 46.655% $(45.006\%$ - $48.549\%)$ 45.972% $(43.697\%$ - $47.010\%)$ 0.011 PUFA 14.699% $(13.652\%$ - $15.906\%)$ 13.974% $(13.295\%$ - $15.146\%)$ 0.563 Σ n-3 1.952% $(1.733\%$ - $2.208\%)$ 1.954% $(1.801\%$ - $2.841\%)$ 0.033 0.015	24:1	0.041% (0.034%-0.049%)	0.040% (0.034%-0.047%)	0.677	
24:40.005% (0.005%-0.006%)0.005% (0.004%-0.005%)0.07124:50.007% (0.005%-0.008%)0.006% (0.006%-0.008%)0.92824:60.005% (0.004%-0.006%)0.006% (0.005%-0.007%)0.18026:00.002% (0.002%-0.004%)0.003% (0.002%-0.004%)0.04826:10.006% (0.005%-0.007%)0.90126:20.008% (0.007%-0.011%)0.008% (0.006%-0.011%)0.51726:30.003% (0.002%-0.004%)0.003% (0.002%-0.004%)0.633SFA38.547% (36.940%-39.937%)40.323% (38.769%-41.630%)<0.001#	24:3	0.002% (0.001%-0.002%)	0.002% (0.001%-0.002%)	0.442	
24:5 $0.007\% (0.005\% - 0.008\%)$ $0.006\% (0.006\% - 0.008\%)$ 0.928 24:6 $0.005\% (0.004\% - 0.006\%)$ $0.006\% (0.005\% - 0.007\%)$ 0.180 26:0 $0.002\% (0.002\% - 0.004\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.048 0.979 26:1 $0.006\% (0.005\% - 0.007\%)$ $0.006\% (0.005\% - 0.007\%)$ 0.901 26:226:2 $0.008\% (0.007\% - 0.011\%)$ $0.008\% (0.006\% - 0.011\%)$ 0.517 26:3 $0.003\% (0.002\% - 0.004\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.633 SFA $38.547\% (36.940\% - 39.937\%)$ $40.323\% (38.769\% - 41.630\%)$ <0.001 MUFA $46.655\% (45.006\% - 48.549\%)$ $45.972\% (43.697\% - 47.010\%)$ 0.011 0.014 PUFA $14.699\% (13.652\% - 15.906\%)$ $13.974\% (13.295\% - 15.146\%)$ 0.059 Σ n-3 $1.952\% (1.733\% - 2.208\%)$ $1.954\% (1.801\% - 2.184\%)$ 0.033 0.015 Σ n-6 $12.325\% (11.493\% - 13.775\%)$ $11.792\% (11.004\% - 12.841\%)$ 0.033 0.015	24:4	0.005% (0.005%-0.006%)	0.005% (0.004%-0.005%)	0.071	
24:60.005% (0.004%-0.006%)0.006% (0.005%-0.007%)0.18026:00.002% (0.002%-0.004%)0.003% (0.002%-0.004%)0.0480.97926:10.006% (0.005%-0.007%)0.9010.90126:20.008% (0.007%-0.011%)0.008% (0.006%-0.011%)0.51726:30.003% (0.002%-0.004%)0.003% (0.002%-0.004%)0.633SFA38.547% (36.940%-39.937%)40.323% (38.769%-41.630%)<0.001#	24:5	0.007% (0.005%-0.008%)	0.006% (0.006%-0.008%)	0.928	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	24:6	0.005% (0.004%-0.006%)	0.006% (0.005%-0.007%)	0.180	
26:1 $0.006\% (0.005\% - 0.007\%)$ $0.006\% (0.005\% - 0.007\%)$ 0.901 26:2 $0.008\% (0.007\% - 0.011\%)$ $0.008\% (0.006\% - 0.011\%)$ 0.517 26:3 $0.003\% (0.002\% - 0.004\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.633 SFA $38.547\% (36.940\% - 39.937\%)$ $40.323\% (38.769\% - 41.630\%)$ <0.001 #MUFA $46.655\% (45.006\% - 48.549\%)$ $45.972\% (43.697\% - 47.010\%)$ 0.011 PUFA $14.699\% (13.652\% - 15.906\%)$ $13.974\% (13.295\% - 15.146\%)$ 0.059 Σ n-3 $1.952\% (1.733\% - 2.208\%)$ $1.954\% (1.801\% - 2.184\%)$ 0.563 Σ n-6 $12.325\% (11.493\% - 13.775\%)$ $11.792\% (11.004\% - 12.841\%)$ 0.033 0.015	26:0	0.002% (0.002%-0.004%)	0.003% (0.002%-0.004%)	0.048	0.979
26:2 $0.008\% (0.007\% - 0.011\%)$ $0.008\% (0.006\% - 0.011\%)$ 0.517 26:3 $0.003\% (0.002\% - 0.004\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.633 SFA $38.547\% (36.940\% - 39.937\%)$ $40.323\% (38.769\% - 41.630\%)$ $<0.001^{\#}$ MUFA $46.655\% (45.006\% - 48.549\%)$ $45.972\% (43.697\% - 47.010\%)$ 0.011 0.014 PUFA $14.699\% (13.652\% - 15.906\%)$ $13.974\% (13.295\% - 15.146\%)$ 0.059 Σ n-3 $1.952\% (1.733\% - 2.208\%)$ $1.954\% (1.801\% - 2.184\%)$ 0.563 Σ n-6 $12.325\% (11.493\% - 13.775\%)$ $11.792\% (11.004\% - 12.841\%)$ 0.033 0.015	26:1	0.006% (0.005%-0.007%)	0.006% (0.005%-0.007%)	0.901	
26:3 $0.003\% (0.002\% - 0.004\%)$ $0.003\% (0.002\% - 0.004\%)$ 0.633 SFA $38.547\% (36.940\% - 39.937\%)$ $40.323\% (38.769\% - 41.630\%)$ $<0.001^{\#}$ MUFA $46.655\% (45.006\% - 48.549\%)$ $45.972\% (43.697\% - 47.010\%)$ 0.011 0.014 PUFA $14.699\% (13.652\% - 15.906\%)$ $13.974\% (13.295\% - 15.146\%)$ 0.059 Σ n-3 $1.952\% (1.733\% - 2.208\%)$ $1.954\% (1.801\% - 2.184\%)$ 0.563 Σ n-6 $12.325\% (11.493\% - 13.775\%)$ $11.792\% (11.004\% - 12.841\%)$ 0.033 0.015	26:2	0.008% (0.007%-0.011%)	0.008% (0.006%-0.011%)	0.517	
SFA 38.547% (36.940% - 39.937%) 40.323% (38.769% - 41.630%) <0.001 # <0.001 MUFA 46.655% (45.006% - 48.549%) 45.972% (43.697% - 47.010%) 0.011 0.014 PUFA 14.699% (13.652% - 15.906%) 13.974% (13.295% - 15.146%) 0.059 Σ n-3 1.952% (1.733% - 2.208%) 1.954% (1.801% - 2.184%) 0.563 Σ n-6 12.325% (11.493% - 13.775%) 11.792% (11.004% - 12.841%) 0.033 0.015	26:3	0.003% (0.002%-0.004%)	0.003% (0.002%-0.004%)	0.633	
MUFA 46.655% (45.006%-48.549%) 45.972% (43.697%-47.010%) 0.011 0.014 PUFA 14.699% (13.652%-15.906%) 13.974% (13.295%-15.146%) 0.059 Σ n-3 1.952% (1.733%-2.208%) 1.954% (1.801%-2.184%) 0.563 Σ n-6 12.325% (11.493%-13.775%) 11.792% (11.004%-12.841%) 0.033 0.015	SFA	38.547% (36.940%-39.937%)	40.323% (38.769%-41.630%)	<0.001#	<0.001
PUFA 14.699% (13.652%-15.906%) 13.974% (13.295%-15.146%) 0.059 Σ n-3 1.952% (1.733%-2.208%) 1.954% (1.801%-2.184%) 0.563 Σ n-6 12.325% (11.493%-13.775%) 11.792% (11.004%-12.841%) 0.033 0.015	MUFA	46.655% (45.006%-48.549%)	45.972% (43.697%-47.010%)	0.011	0.014
Σ n-3 1.952% (1.733%-2.208%) 1.954% (1.801%-2.184%) 0.563 Σ n-6 12.325% (11.493%-13.775%) 11.792% (11.004%-12.841%) 0.033 0.015	PUFA	14.699% (13.652%-15.906%)	13.974% (13.295%-15.146%)	0.059	
Σ n-6 12.325% (11.493%-13.775%) 11.792% (11.004%-12.841%) 0.033 0.015	Σn-3	1.952% (1.733%-2.208%)	1.954% (1.801%-2.184%)	0.563	
	_ Σ n-6	12.325% (11.493%-13.775%)	11.792% (11.004%-12.841%)	0.033	0.015
n-6/n-3 6.435% (5.819%-7.130%) 6.117% (5.283%-6.806%) 0.020 0.045	 n-6/n-3	6.435% (5.819%-7.130%)	6.117% (5.283%-6.806%)	0.020	0.045

(Continued)

Table 3. (Continued)

	post-GDM	controls	p-value*	BMI and HbA1c adj. p-value**
SCD-1 (18:1/18:0)	4.697 (4.164–5.317)	4.205 (3.908–4.747)	0.010	0.013
EloVL6 (18:0/16:0)	0.341 (0.315–0.373)	0.346 (0.318–0.384)	0.329	
Δ-5 D (20:4/20:3)	3.720 (3.058–4.314)	3.554 (3.253–4.119)	0.917	
Total NEFA _{LC-MS/MS}	485.1 μM (402.8 μM -622.4 μM)	485.42 μM (408.1 μM -594.0 μM)	0.981	
Total NEFA _{Enzymatic Test}	564.5 μM (407.0 μM -668.0 μM)	548.0 μM (444.0 μM -681.0 μM)	0.805	

Percentage concentrations (mol%) and absolute concentrations of NEFA are given as medians with interquartile ranges. n = 62 for the cases and n = 49 for the controls.

*Mann-Whitney U tests.

**Logistic regression analyses were adjusted for BMI and HbA1c when p<0.05 from Mann-Whitney U test. #Significant after Bonferroni correction.

doi:10.1371/journal.pone.0128001.t003

between the groups existed in the NEFA composition. Women after GDM had a lower proportion of SFA and, at an exploratory level of significance, higher proportions of linoleic acid (18:2 n-6) and total n-6 NEFA. These differences were unchanged after adjustment for BMI and HbA1c. In a combined analysis of all study participants we also found positive as well as negative associations of several NEFA species with overweight/obesity. 14:0 and partially also 12:0 were inversely associated with abdominal visceral adiposity after adjustment for total body fat.

Women after GDM have an at least 10-fold increased risk of developing T2D later in life but are normoglycemic early after the index pregnancy in most cases [14]; thus, this population provides a unique opportunity to study an at-risk phenotype for T2D under normoglycemic conditions. This predisposition for T2D was also visible in our cross sectional data. Although the distributions of BMI, fat mass, liver fat, blood pressure, triglycerides and HDL/LDL cholesterol of the post-GDM group were similar to those of controls, the Matsuda Index and the Disposition Index were both significantly decreased. Hence, reduced insulin sensitivity and impaired beta-cell function were already present in these normoglycemic at-risk subjects.

Fasting serum NEFA are not directly derived from nutritional intake but primarily originate from adipose tissue storages [26, 27]. Thus, the association between the fatty acid composition of the adipose tissue and the NEFA profile in the fasting serum is strong [28]. Adipose tissue fatty acids are long-term markers of dietary fatty acid intake [21, 29] but also result from enzy-matic modifications. Primarily, elongases and desaturases as well as enzymes involved in oxidation pathways affect fatty acid composition. The fatty acid-modifying enzymes for which connections to insulin resistance and T2D have been shown include delta-5, delta-6 and delta-9 desaturases (SCD-1) and elongase EloVL6 [30, 31]. SCD-1 is of particular interest because it is the rate-limiting step in the transformation of proinflammatory SFA to MUFA [32, 33].

The significant difference in the SFA proportion between women after GDM and controls that we observed was small (median 38.6% vs. 40.3%) but independent of BMI and HbA1c. Its biological relevance nevertheless remains uncertain. Our results suggest that the lower proportion of SFA in the post-GDM group was caused by endogenous transformation of SFA to MUFA and not by different nutritional intake. However, it is possible that the food frequency questionnaire did not adequately represent all aspects of fatty acid intake. Nevertheless the calculated activity of SCD-1 was elevated in the women after GDM and inversely correlated with the SFA proportion. Our approach to estimate SCD-1 activity has been shown to reflect subcutaneous adipose tissue SCD-1 expression [34]. We previously showed that elevated plasma fetuin-A, a predictive biomarker for T2D [35, 36], is also an independent risk marker in women with a recent history of GDM [15]. This finding was replicated in the present study.



Fig 1. Altered NEFA pathways in cases compared to controls. At an exploratory level of significance (p<0.05), the women after GDM exhibited reduced levels of 12:0, 14:0, 16:0, 18:0, 26:0 and total SFA and elevated levels of 18:1, the essential fatty acid 18:2, total n-6 NEFA and the proportion of total n-6/n-3 NEFA. Calculated SCD-1 activity was significantly increased in the post-GDM group. Only total SFA remained significantly different after Bonferroni correction. The red arrows in the diagram represent upregulation, and the blue arrows represent downregulation in the post-GDM group.

doi:10.1371/journal.pone.0128001.g001

PLOS | ONE

Since fetuin-A co-signals with SFA to induce adipose tissue inflammation [37], one possible explanation for the lower SFA proportions in normoglycemic women after GDM is that this constitutes a compensatory response to higher fetuin-A concentrations. However, at this point this remains speculative.

At an exploratory level of significance we also found higher levels of the essential fatty acid linoleic acid (18:2 n-6) and total n-6 NEFA in the post-GDM group. These NEFA species are linked to inflammatory signaling, insulin resistance and T2D risk [38, 39]. Nutritional advice for a 18:2-poor diet might therefore have the beneficial effect of less arachidonic acid (20:4 n-6) production and anti-inflammatory eicosanoid synthesis [40] in individuals at risk for T2D, in particular in women with GDM.

Correlations between distinct saturated fatty acids including 12:0, 14:0 and 18:0 and insulin sensitivity were previously shown in 70 year old men with established T2D by Iggman et al.



	BMI	Body fat _{BIA}	WC	WC (adjusted for BMI)	Total fat volume (MRI)	Abdominal fat volume (MRI)	Abdominal fat volume (adjusted for total fat volume, MRI)
12:0	-0.323***	-0.355***	-0.424***	-0.305**	225	-0.272*	-0.156
14:0	-0.372***	-0.417***	-0.480***	-0.340***	-0.473***	-0.533***	-0.290*
15:0	-0.206*	-0.279**	-0.273**	-0.192	-0.340**	-0.296*	-0.041
15:1	-0.202*	-0.244*	-0.278**	-0.209*	-0.256*	-0.314*	-0.188
16:3	0.287**	0.326***	0.290**	0.089	0.340**	0.285*	0.021
18:2	0.236*	0.210*	0.244*	0.083	0.285*	0.345**	0.202
20:0	-0.392***	-0.414***	-0.353***	-0.032	-0.451***	-0.363**	-0.001
20:1	-0.238*	-0.216*	-0.233*	-0.055	-0.340**	-0.308*	-0.062
22:4	0.312**	0.336***	0.343***	0.154	0.392**	0.412***	0.176
26:2	0.273**	0.326***	0.323***	0.178	0.342**	0.315*	0.072
26:3	0.297**	0.360***	0.386***	0.269**	0.261*	0.263*	0.093

|--|

All nonesterified fatty acid (NEFA) species with a Spearman correlation coefficient $\rho \ge 0.3$ with any of the listed parameters of body composition are shown in the table. The post-GDM and the control group were combined for this analysis. n = 106 for BMI, WC and percent body fat measured by BIA. n = 62 for the MRI substudy.

*Correlation is significant with p<0.05.

**Correlation is significant with p<0.01.

***Correlation is significant with p<0.001.

doi:10.1371/journal.pone.0128001.t004

[41]. We were unable to reproduce these observations, probably due to the different study populations. We found that the saturated fatty acids 12:0, 14:0, 15:0, 20:0, as well as the monounsaturated fatty acids 15:1 and 20:1, were inversely correlated with BMI and other parameters of adiposity in our study. 16:3, 18:2, 22:4, 26:2 and 26:3 showed positive correlations. These BMIassociated changes in the fasting serum NEFA might be related to pathologic alterations of the adipose tissue in obesity, e.g. adipocyte hypertrophy [42]. The SFA 14:0 and to a lesser extent 12:0 were particularly interesting with respect to body composition because they showed an inverse association with visceral adiposity in a BMI-independent manor. A low serum concentration of 14:0 has recently also been identified as a biomarker of T2D [43]. This link may be explained by the inverse association of 14:0 with visceral obesity that we saw in our analysis.

The major strength of our study is the consecutively recruited, normoglycemic cohort of young women with very few confounding diseases or medications. Limitations include the cross-sectional study design, which precludes propositions about causality and the prognostic relevance of our findings. Cohort size also limited the statistical power of some of our analyses. We also cannot exclude the possibility that our findings in part represent changes that are induced by the prior GDM or its treatment. However, nutritional information collected by food frequency questionnaire showed no differences between the post-GDM and the control group. Finally, it is unclear to what extent findings from a cohort of young women can be transferred to the general population.

In conclusion, this study shows differences in the fasting serum NEFA profile between women with a recent history of GDM, i.e. a high risk group for T2D, and control subjects. The NEFA composition also varied with overweight/obesity but not with insulin sensitivity. These findings are probably only in part related to fatty acid intake and mostly the result of enzymatic modifications. Our data should be confirmed in larger clinical cohorts and experimental evidence will be required to test their pathophysiological relevance.

Supporting Information

S1 Table. Group comparisons of the EPIC-FFQ data. (DOCX)

S2 Table. Overview of the associations between fasting serum NEFA profiles and EPIC-FFQ data regarding the sums of the SFA, MUFA and PUFA. (DOCX)

Acknowledgments

We are grateful to all participants of the PPS-Diab study. This paper is part of the Ph.D. thesis of Marina Fugmann at the Medical Faculty of the Ludwig-Maximilians-Universität München in Munich, Germany.

Author Contributions

Conceived and designed the experiments: MF OU CH UF KGP BK JS AL. Performed the experiments: MF OU CH HH NNK UF. Analyzed the data: MF AL. Wrote the paper: MF OU CH HH NNK UF KGP BK JS AL.

References

- 1. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002; 51(1):7–18. PMID: <u>11756317</u>.
- Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003; 52(10):2461–74. PMID: <u>14514628</u>.
- Roden M. Does endurance training protect from lipotoxicity? Diabetes. 2012; 61(10):2397–9. Epub 2012/09/22. doi: <u>10.2337/db12-0662</u> PMID: <u>22997429</u>; PubMed Central PMCID: PMC3447918.
- Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nature reviews Molecular cell biology. 2008; 9(5):367–77. Epub 2008/04/ 11. doi: <u>10.1038/nrm2391</u> PMID: <u>18401346</u>; PubMed Central PMCID: PMC2886982.
- Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444(7121):840–6. Epub 2006/12/15. doi: <u>10.1038/nature05482</u> PMID: <u>17167471</u>.
- Il'yasova D, Wang F, D'Agostino RB Jr., Hanley A, Wagenknecht LE. Prospective association between fasting NEFA and type 2 diabetes: impact of post-load glucose. Diabetologia. 2010; 53(5):866–74. Epub 2010/02/10. doi: <u>10.1007/s00125-010-1657-4</u> PMID: <u>20143044</u>; PubMed Central PMCID: PMC3660100.
- Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Mechanism of free fatty acid-induced insulin resistance in humans. The Journal of clinical investigation. 1996; 97(12):2859–65. doi: <u>10.1172/JCl118742</u> PMID: <u>8675698</u>; PubMed Central PMCID: PMC507380.
- Hara T, Kimura I, Inoue D, Ichimura A, Hirasawa A. Free fatty acid receptors and their role in regulation of energy metabolism. Reviews of physiology, biochemistry and pharmacology. 2013; 164:77–116. Epub 2013/04/30. doi: <u>10.1007/112_2013_13</u> PMID: <u>23625068</u>.
- Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. The Journal of clinical investigation. 2006; 116(11):3015–25. Epub 2006/10/ 21. doi: 10.1172/JCI28898 PMID: 17053832; PubMed Central PMCID: PMC1616196.
- Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010; 142(5):687–98. Epub 2010/09/04. doi: <u>10.1016/j.cell.2010.07.041</u> PMID: <u>20813258</u>; PubMed Central PMCID: PMC2956412.
- Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW. Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PloS one. 2012; 7(11):e48852. Epub 2012/11/13. doi: <u>10.1371/journal.pone.0048852</u> PMID: <u>23144998</u>; PubMed Central PMCID: PMC3493609.
- 12. Novgorodtseva TP, Karaman YK, Zhukova NV, Lobanova EG, Antonyuk MV, Kantur TA. Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome.

Lipids in health and disease. 2011; 10:82. Epub 2011/05/21. doi: <u>10.1186/1476-511X-10-82</u> PMID: <u>21595891</u>; PubMed Central PMCID: PMC3116500.

- Verma A, Boney CM, Tucker R, Vohr BR. Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. The Journal of clinical endocrinology and metabolism. 2002; 87(7):3227– 35. Epub 2002/07/11. doi: <u>10.1210/jcem.87.7.8684</u> PMID: <u>12107230</u>.
- Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne. 2008; 179(3):229–34. doi: <u>10.1503/cmaj.080012</u> PMID: <u>18663202</u>; PubMed Central PMCID: PMC2474881.
- Rottenkolber M, Ferrari U, Holland L, Aertsen S, Kammer NN, Hetterich H, et al. The diabetes risk phenotype of young women with recent gestational diabetes. The Journal of clinical endocrinology and metabolism. 2015;jc20143898. doi: <u>10.1210/jc.2014-3898</u> PMID: <u>25742512</u>.
- IADPSG, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes care. 2010; 33(3):676–82. doi: <u>10.2337/dc09-1848</u> PMID: <u>20190296</u>; PubMed Central PMCID: PMC2827530.
- 17. Kroke A, Klipstein-Grobusch K, Voss S, Moseneder J, Thielecke F, Noack R, et al. Validation of a self-administered food-frequency questionnaire administered in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study: comparison of energy, protein, and macronutrient intakes estimated with the doubly labeled water, urinary nitrogen, and repeated 24-h dietary recall methods. The American journal of clinical nutrition. 1999; 70(4):439–47. Epub 1999/09/29. PMID: 10500011.
- Hu HH, Nayak KS, Goran MI. Assessment of abdominal adipose tissue and organ fat content by magnetic resonance imaging. Obesity reviews: an official journal of the International Association for the Study of Obesity. 2011; 12(5):e504–15. Epub 2011/02/26. doi: <u>10.1111/j.1467-789X.2010.00824.x</u> PMID: 21348916; PubMed Central PMCID: PMC3079791.
- Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. Journal of magnetic resonance imaging: JMRI. 2011; 34(4):spcone. Epub 2011/10/26. doi: <u>10.1002/jmri.22775</u> PMID: <u>22025886</u>; PubMed Central PMCID: PMC3177109.
- Hellmuth C, Weber M, Koletzko B, Peissner W. Nonesterified fatty acid determination for functional lipidomics: comprehensive ultrahigh performance liquid chromatography-tandem mass spectrometry quantitation, qualification, and parameter prediction. Analytical chemistry. 2012; 84(3):1483–90. Epub 2012/01/10. doi: 10.1021/ac202602u PMID: 22224852.
- Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Progress in lipid research. 2008; 47(5):348–80. Epub 2008/04/ 26. doi: <u>10.1016/j.plipres.2008.03.003</u> PMID: <u>18435934</u>.
- Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes care. 1999; 22(9):1462–70. Epub 1999/09/10. PMID: <u>10480510</u>.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412–9. Epub 1985/07/01. PMID: <u>3899825</u>.
- Abdul-Ghani MA, Molina-Carrion M, Jani R, Jenkinson C, Defronzo RA. Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin. Acta diabetologica. 2008; 45(3):147–50. Epub 2008/03/22. doi: <u>10.1007/s00592-008-0033-z</u> PMID: <u>18357404</u>.
- Lorenzo C, Wagenknecht LE, Rewers MJ, Karter AJ, Bergman RN, Hanley AJ, et al. Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes care. 2010; 33(9):2098–103. doi: <u>10.2337/dc10-0165</u> PMID: <u>20805282</u>; PubMed Central PMCID: PMC2928371.
- Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes. 2011; 60(10):2441–9. doi: <u>10.2337/db11-0425</u> PMID: <u>21948998</u>; PubMed Central PMCID: PMC3178283.
- Koutsari C, Dumesic DA, Patterson BW, Votruba SB, Jensen MD. Plasma free fatty acid storage in subcutaneous and visceral adipose tissue in postabsorptive women. Diabetes. 2008; 57(5):1186–94. doi: <u>10.2337/db07-0664</u> PMID: <u>18285557</u>.
- Hellmuth C, Demmelmair H, Schmitt I, Peissner W, Bluher M, Koletzko B. Association between plasma nonesterified fatty acids species and adipose tissue fatty acid composition. PloS one. 2013; 8(10): e74927. doi: <u>10.1371/journal.pone.0074927</u> PMID: <u>24098359</u>; PubMed Central PMCID: PMC3788793.
- 29. Baylin A, Kabagambe EK, Siles X, Campos H. Adipose tissue biomarkers of fatty acid intake. The American journal of clinical nutrition. 2002; 76(4):750–7. Epub 2002/09/27. PMID: 12324287.

- Vessby B, Gustafsson IB, Tengblad S, Boberg M, Andersson A. Desaturation and elongation of Fatty acids and insulin action. Annals of the New York Academy of Sciences. 2002; 967:183–95. Epub 2002/ 06/25. PMID: <u>12079847</u>.
- Matsuzaka T, Shimano H. Elovl6: a new player in fatty acid metabolism and insulin sensitivity. J Mol Med (Berl). 2009; 87(4):379–84. Epub 2009/03/05. doi: <u>10.1007/s00109-009-0449-0</u> PMID: <u>19259639</u>.
- Liu X, Strable MS, Ntambi JM. Stearoyl CoA desaturase 1: role in cellular inflammation and stress. Adv Nutr. 2011; 2(1):15–22. Epub 2012/01/03. doi: <u>10.3945/an.110.000125</u> PMID: <u>22211186</u>; PubMed Central PMCID: PMC3042787.
- Fessler MB, Rudel LL, Brown JM. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Current opinion in lipidology. 2009; 20(5):379–85. doi: <u>10.1097/MOL.0b013e32832fa5c4</u> PMID: <u>19625959</u>; PubMed Central PMCID: PMC3099529.
- Sjogren P, Sierra-Johnson J, Gertow K, Rosell M, Vessby B, de Faire U, et al. Fatty acid desaturases in human adipose tissue: relationships between gene expression, desaturation indexes and insulin resistance. Diabetologia. 2008; 51(2):328–35. Epub 2007/11/22. doi: <u>10.1007/s00125-007-0876-9</u> PMID: <u>18030445</u>.
- Sun Q, Cornelis MC, Manson JE, Hu FB. Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. Diabetes. 2013; 62(1):49–55. Epub 2012/08/28. doi: <u>10.2337/</u> <u>db12-0372</u> PMID: <u>22923470</u>; PubMed Central PMCID: PMC3526056.
- Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008; 57(10):2762–7. Epub 2008/07/18. doi: <u>10.2337/db08-0538</u> PMID: <u>18633113</u>; PubMed Central PMCID: PMC2551687.
- Heinrichsdorff J, Olefsky JM. Fetuin-A: the missing link in lipid-induced inflammation. Nature medicine. 2012; 18(8):1182–3. Epub 2012/08/08. doi: <u>10.1038/nm.2869</u> PMID: <u>22869185</u>.
- **38.** Calder PC. Fatty acids and inflammation: the cutting edge between food and pharma. European journal of pharmacology. 2011; 668 Suppl 1:S50–8. doi: <u>10.1016/j.ejphar.2011.05.085</u> PMID: <u>21816146</u>.
- Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnology journal. 2006; 1 (4):420–39. doi: <u>10.1002/biot.200600012</u> PMID: <u>16892270</u>.
- Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C. Health implications of high dietary omega-6 polyunsaturated Fatty acids. Journal of nutrition and metabolism. 2012; 2012:539426. doi: <u>10.1155/</u> 2012/539426 PMID: <u>22570770</u>; PubMed Central PMCID: PMC3335257.
- Iggman D, Arnlov J, Vessby B, Cederholm T, Sjogren P, Riserus U. Adipose tissue fatty acids and insulin sensitivity in elderly men. Diabetologia. 2010; 53(5):850–7. doi: <u>10.1007/s00125-010-1669-0</u> PMID: <u>20127308</u>.
- Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert review of cardiovascular therapy. 2008; 6(3):343–68. doi: <u>10.1586/14779072.6.3.343</u> PMID: 18327995.
- Menni C, Fauman E, Erte I, Perry JR, Kastenmuller G, Shin SY, et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes. 2013; 62 (12):4270–6. doi: 10.2337/db13-0570 PMID: 23884885; PubMed Central PMCID: PMC3837024.